F.D.A. Moves to Speed Approvals for Cheaper Copycat Drugs
Health
By Rebecca Robbins from NYT Health https://ift.tt/VBFW9eC
via IFTTT Regulation and Deregulation of Industry, Prices (Fares, Fees and Rates), Biotechnology and Bioengineering, Drugs (Pharmaceuticals), Generic Brands and Products, Clinical Trials, Inventions and Patents The agency announced moves to cut regulatory obstacles for the makers of biosimilar drugs, which are akin to generics and may help lower drug costs.

By Rebecca Robbins from NYT Health https://ift.tt/VBFW9eC
via IFTTT Regulation and Deregulation of Industry, Prices (Fares, Fees and Rates), Biotechnology and Bioengineering, Drugs (Pharmaceuticals), Generic Brands and Products, Clinical Trials, Inventions and Patents The agency announced moves to cut regulatory obstacles for the makers of biosimilar drugs, which are akin to generics and may help lower drug costs.
Comments
Post a Comment